RC48-ADC in HER2-low Advanced Breast Cancer

To evaluate the efficacy and safety of Disitamab vedotin (RC48-ADC) as salvage treatment in patients with HER2-low advanced breast cancer who have received up to one previous chemotherapy for recurrent or metastatic disease without previous use of antibody-drug conjugate.

Trial Details

NCT ID
NCT05831878
Phase
NA
Sponsor
RenJi Hospital
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Disitamab vedotin
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Female patients aged ≥18 years
  • Expected survival ≥12 weeks
  • Histologically confirmed invasive advanced or metastatic breast cancer that is incurable and unresectable
  • At least one measurable lesion according to the RECIST 1.1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →